Usa India hospital covid-19 patient Usa India

Gilead says remdesivir helped moderate COVID-19 patients improve

Reading now: 530
www.livemint.com

Gilead said antiviral drug remdesivir reduced hospitalization stays by 31%, or about four days, compared to a placebo Gilead Sciences Inc said on Monday results from a study showed its antiviral drug remdesivir demonstrated significantly greater clinical improvement in patients with moderate COVID-19.

Remdesivir is being closely watched after the US Food and Drug Administration granted emergency use authorization on May 1, citing results from another study run by the National Institutes of Health that showed the drug reduced hospitalization stays by 31%, or about four days, compared to a placebo.

The new results announced by Gilead are from a study designed to evaluate the safety and efficacy of 5- and 10-day treatment with remdesivir in

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA